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INVITED REVIEW The acquired demyelinating polyneuropathies include acute (AIDP, Guil- 
lain-Barre syndrome, GBS) and chronic (CIDP, dysproteinemic) forms 
which differ primarily in their temporal profile. They are inflammatory-demy- 
elinating diseases of the peripheral nervous System and likely have an im- 
munologic pathogenesis. Although these neuropathies usually have a char- 
acteristic presentation, the electromyographer plays a central role in their 
recognition, since the demyelinating component of the neuropathy, which 
greatly reduces the differential diagnosis, is often first identified in the elec- 
tromyography laboratory. In AIDP, the electromyographer, in addition to es- 
tablishing the diagnosis, can sometimes predict the prognosis. Recognition 
of the chronic and dysproteinemic forms of acquired demyelinating poly- 
neuropathy is important since they are treatable. The dysproteinemic forms 
also may be associated with occult systemic disorders that also may re- 
quire treatment, independent of the neuropathy. 
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Polyneuropat~iies arc frequently (I 
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myelinatirig type, ir i t  luding ‘tc utc m c l  c h r  onic 
forms tlif feririg prirn,irily in their tcnipornl pio- 
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‘ition. Specific etiologies have not been identified, 
but ininiunologic rncchanisrns dmost cer tairily are 
involvcct. A ~ n ~ i j o r  ativanc e has heen the recogni- 
tion a i i d  iiiicter~tariclirig of ctcmyelinating ne~i i  op- 
‘ i t k i i o  r i ~ s o c  iated with plasma (ell dysc rasias. Al- 
though lewer in riurnber, they are important 
Ixx < I I I S C  the c i r c  ulntiiig rrionoclonal protein itself 
likely dnmage5 iici vc  fibers. Under standing the 
iriec h a n i ~ n i s  involved rnny help clarify the nicc ha- 
ii5riis  of other obscure neuropathies, as well. 1 lie 
evnluatiori of patients with suspected acute inflam- 
malory dcniyclinating polyneuropathy (AIDI’, 
(;iiillaiii-lSarrk syndrome, GISS), or c hronic in- 
flarnriiatoi y tlernyelinating polyneuropath y (CIDP) 
iricliitics clct trodiagnostic examination, such as 
th‘it shown in Table I .  Ihis examination is di- 
rcc tcd tow,ird detec ting evidence of segnierital or 
rnirltifocal ttcrnyelinatiori. 
ACUTE INFLAMMATORY DEMYELINATING 
POLYNEUROPATHY 
Clinical Features. T h e  incitlcrice of AIIIP is 0.5- 
1 . ~ ~ / r ~ i i l l i o i i / r i i ~ ~ r i t l ~ ,  increasirig slightly with advanc- 
ing agc until about 75 ycary, nnd tlirniniShirig 
thereaf~er.” I’here are 1 1 0  known genetic o r  geo- 
graphic predilections, although incitlerice is 
slightly tiig~rcr for men tIiari for woincn 1)1‘1g- 
riostic t i iter ia ai e ( t c w  iptive arid based upon r cc- 
ogiiition of ;I relatively ( hnracteristic clinical 
pic ture.” ‘1 ypic a1 firitlings i n c  ~ u d e  rapicily progres- 
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Table 1. Suspected inflammatory-demyelinating polyneuropathy suggested electrodiagnostic protocol 
Conduction Studiesa 





6 .  
7 .  
8 .  
Test most involved site when mild or moderate, least involved if severe. 
Evaluate the peroneal motor (extensor digitorum brevis); stimulate ankle, fibular head, and knee. Measure the F response 
latency.b 
If abnormal, evaluate the tibial motor (abductor hallucis); stimulate ankle and knee. Measure the F response latency. 
If no responses, evaluate the 
a. Peroneal motor (anterior tibial); stimulate fibula head and knee. 
b. Ulnar motor (hypothenar); stimulate clavicle, elbow, below elbow, and wrist. Measure the F response latency. 
c.  Median motor (thenar); stimulate elbow and wrist. Measure the F response latency. 
Evaluate the sural sensory (ankle); stimulate 14 cm from recording electrode; perform conduction velocity unless the 
arnplitude is supernormal. 
Evaluate the rnedian sensory (index); stimulate the wrist and elbow. If antidromic response is absent or focal entrapment is 
suspected, record from the wrist while stimulating the palm. 
Additional peripheral nerves can be evaluated if findings are equivocal. Definite abnormalities should result in 
a. Evaluation of contralateral extremity 
b .  Proceeding to evaluation of specific suspected abnormality 
If promiriarit cranial involvement: 
a. Evaluate the facial motor (orbicularis oculi): stimulate at the angle of jaw. 
b. Conduct blink reflex studies (orbicularis oculi): stimulate the supraorbital nerve. 
Needle Examination 
1 Exarriine the anterior tibial, medial gastrocnemius, vastus lateralis, biceps brachii, interosseous (hand), and lumbar paraspirial 
muscles 
2 Any abnormality should be confirmed by exarrination of at least one contralateral muscle 
Source Modified and reprinted from Ref 2 with the permission of John Wdey & Sons Inc Copyright 0 1985 
VVords in parentheses indicate recording site for conduclion studies 
bA// F response latericy measurements are for distal stimulafion sites on/) 
sive weakness, often with bulbar and respiratory 
iiivolvemeiit; liyporef-lexia or  areflexia; slightly di- 
minished sensation; autonomic dysfunction; and 
cerebrospinal fluid (CSF) protein elevation with- 
An antecedent event, most commonly a respi- 
ratory tract infection or gastroenteritis, is evident 
within 1 nionth (an average of 15 days) in over 
(iO% of' ~iat ients .~ Other antecedent events include 
other infections (e.g., hepatitis 13, Epstein--Barr 
virus, cytornegalovirus, toxoplasmosis), immuniza- 
tioii,83 malignant disease, and surgery.5 AIDP also 
has been associated with acquired HIVl infec- 
tions, Lyrne disease, Hodgkin's disease, and non- 
Hodgkin's lymphoma.59 
Initial manifestations include syrrinietrical mo- 
tor and/or sensory syniptorns.4 -I'he niost common 
complaint is leg weakness,5 and many patierits 
demonstract spread in a distal-to-proximal fash- 
ion. Prominent. facial weakness occurs in about 
50% of  patient^,^ anti  unilateral facial involverrielit 
tias been described in up to 10% of patients,4 con- 
sistent with an isolated mononeuropathy superim- 
posed on a generalized polyneuropathy. Other 
cranial nerve involvement leads to weakness of 
mastication, swallowing, and, rarely, eye move- 
ments." Despite common sensory symptoms, ob- 
jective sensory loss is infrequent. ''' When present, 
out p]eocytosis."7.48,"8.88."" 
large myelinated fiber modalities (vibratory and 
joint position sensations) are involved. Back arid 
extremity pain are frequent complaints during the 
early stages of the illness and may be severe. 
Autonomic nervous system involvement in- 
cludes bowel and bladder impairment, cardiac 
dysrhythmia, labile heart rate and blood pressure 
resulting in hypertension or hypotension, and 
impaired thermoregulation."~~ The syndrome of 
inappropriate antidiuretic hormone secretion 
(SIADH) has been associated with AIDP, perhaps 
related to abnormalities of autonomic afferents 
arising from vascular stretch receptors."8375 
The Fisher syndrome is considered a variant of 
AIDP, consisting of ophthalmoplegia, ataxia, and 
areflexia.?' I The temporal profile arid CSF h i d -  
ings are indistinguishable from AIUP, and elec- 
trodiagnostic studies in some patierits show a de- 
myelinating polyneuropathy.35 Although some 
consider the syndrome a brainstem encephalitis,"' 
others") propose peripheral explanations for all of 
the clinical signs. 
The interval from the first neurologic syrnp- 
tom to peak impairment is less than 20 days in 
over 75% of  patient^,^ arid 50% of patients reach 
their nadir by 2 weeks.'" Progression exceeding 4 
weeks should be viewed cautiously and alternative 
diagnoses considered. Diaphragm and intercostal 
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muscle involvement leads to respiratory paralysis 
in about 30% of patients. Mechanical ventilation 
usually is initiatcd between 6 and 18 days after on- 
set (mean of 10 days).4 Initial improvement is ob- 
served within 40 days in over 80% of the  patient^,^ 
and the overall prognosis is quite good, with most 
patients demonstratin substantial clinical recov- 
ery within G 111ontlis.~3 
‘The question of relapse in AIDP is difficult be- 
cause of potential confusion with other disorders 
associated with relapsing polyneuropathy, includ- 
ing acute intermittent porphyria,3 systemic lupus 
erythematosus, and the chronic relapsing forms of 
inflammatory polyneuropathy . Distinct relapses in 
patients with otherwise typical AIDP do occur, al- 
though the rate is probably less than 5%. In the 
multicentcred, randomized trial of plasma ex- 
change in the treatment of AIDP,90 four relapses 
were reported out of 254 patients during the 
study period. 
0 
Electrophysiologic Findings. A variety of elec- 
trodiagnostic firidings has been report- 
perhaps due to the temporal 
changes that occur in response to cumulative de- 
myelination and axonal degeneration. The syn- 
drome also may encompass patients with primary 
axonal degeneration as well as patients with severe 
distal conduction block resembling axonal 
degeneration.“0fH’ Nevert.heless, the majority of 
patients demonstrate an evolving picture of a de- 
myelinating polyneuropathy with superimposed 
axonal degeneration.‘ A model of peripheral nio- 
tor nerve, useful in predicting the electrophysio- 
logic firidings in multifocal demyelination, is de- 
,d,‘,29,5 1,62,63,74,78.79 
scribed in the Appendix. Included is a discussion 
of the importance of abnormal temporal disper- 
sion in distinguishing acquired from hereditary 
demyelinating polyr~europathies.~~ 
Studies performed early in the course of 
AIDP, when the diagnosis may be unclear, often 
demonstrate only delayed or absent F responses 
or H reflexes. Occasionally F responses appear 
normal but are difficult to elicit. During subse- 
quent examinations, evidence of segmental con- 
duction block and conduction slowing become ap- 
parent, with abnormal temporal dispersion of 
evoked responses, reduced conduction velocity, 
and prolonged distal latency. ItlenLification of ab- 
normal temporal dispersioii and partial conduc- 
tion block is the most reliable electrodiagnostic in- 
dicator of an acquired demyelinating. folyneurop- 
athy “ but not diagnostic of AIIII’.’’* A charac- 
teristic motor conduction recording fiwn a patient 
with AIDP is shown in Fig. I .  The electrodiagnos- 
tic recognition of primary dem yelination is inipre- 
cise and depends upon identifying abnormalities 
that cannot be explained by axonal involvement 
alone. This differentiation is most straightforward 
in acute disorders in previously well individuals 
without other sources of conduction slowing. Cri- 
teria suggestive of acute dernyelination (Table 2) 
have been modified from those initially proposed 
by Kelly,@‘ recognizing that the distinction be- 
tween “demyelination” and “axonal degeneration” 
is not always clear. 
Evidence of segmental demyelination is pres- 
ent in about 50% of patients during the fjrst 2 
weeks of illness. 1.2 This increases t o  85%’ during 
the third week of illness. Throughout the course 
J y 5 m u  
2ms 
ST I M U L AT E 
ULNAR NERVE 
RECORD FROM Wrist 
LIJ5mV HYPOTHEN AR MUSCLES 
I - & =  ;I”bsow 
-J Imv 
FIGURE 1. Abnormal temporal dispersion with partial conduction block of ulnar compound muscle action potential, recording from hy- 
pothenar muscles of patient with acute inflammatory demyelinating polyneuropathy. 
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Table 2. Criteria suggestive of demyelination in the electrodiagnostic evaluation of acute inflammatory polyneuropathy 
Demonstrate at least three of the following in motor nerves (exceptions noted below) 
1 Conduction velocity less than 90% of lower limit of normal if  amplitude exceeds 50% of lower limit of normal, less than 80% if 
amplitude lcss than 50% of lower limit of normal (two or more nerves) a 
2 Distal latency exceeding 115% of upper limit of riormal if amplitude normal exceeding 125% of upper limit of normal if 
amplitude less than lower limit of normal (two or more nerves) 
3 Evidence of unequivocal temporal dispersion or a proximal to-distal amplitude ratio less than 0 7 (one or more nerves) 
4 F-response latency exceeding 125% of upper limit of nurmal (one or more nerves) a 
Source: Modifred arid reprmted from Ref. 2 with the permission of John Wiley & Sons, Inc., Copyright 0 1985. 
"€xclud!ng isolated ulnar of peroneal nerve abnomalities at the elbow or knee, respectively. 
bExcluding rsoiated median nerve abnormahty at the wrist. 
'€xcluding the presence of anomalous innervation (e g., median to ulnar nerve crossover) 
of' AIDP, 10% of patients never fulfill electrodiag- 
nostic criteria for rlerriyelinat.ion tle(:i>use responses 
are unobtainable. A 4 b o ~ ~ t  3% of patients sr.utlied se- 
quentially dernonstrate evidence of axonal degen- 
eration only. Motor nerve abnormalities peak be- 
tween the third and fourth weeks, although indi- 
vidual patients may demonstrate absent cvoked 
responses within days of onset, presumably re- 
flecting distal conduction block, and/or axonal de- 
generation. Conversely. some patients demon- 
strate progressive amplitude loss through i.hc fifth 
or sixth weeks. Patients having only prolonged di- 
stal latencies during the first 3 weeks of illness5' 
may demonstrate partial conduction block and con- 
duct.ioIi velocity slowing in the following weeks. 
The degree of conduction block, not the 
amourit of motor conduction slowing, best corre- 
lates with clinical impairment. Sequential CI\?IAP 
amplitude recordings for proximal and distal 
stimulation for one patient are shown in Fig. 2. 
The reduced CMAP amplitude with proximal 
stiniulation (clavicle) cannot be explained by t.em- 
pcml dispersion alone and likely represents par- 
tial condiiction block. Early recordings demon- 
strated progressively decreasing amplitudes, re- 
flecting axonal degeneration or  progressive con- 
duction block. During subsequent recordings 
when the neurologic impairment was unchanged, 
the evokctl amplitude with distal stimulation im- 
proved dramatically. This rapid improvement 
cannot be explained by axonal regeneration or 
collateral rcinnervation but is explainable by re- 
versal of distal conduction block. 
During the first few weeks of illness, motor ab- 
normalities ar-e much ~iiore cornnion than sensory 
abnormalities. Motor and sensory evoked ampli- 
tudes expressed as ii percentage of the normal 
mean were averaged for 70 patients with AIDP 
(34 patients had sequential evaluations) versus 
time after disease onset and are shown in Fig. 3.2 
Although almost of patients have SOIIIC ino- 
tor conduction abnormalities during the first few 
weeks of illness, only 2570 of patients have sensory 
abnormalities during the same interval. Ry the 
third week, however, almost 80% of palierits had 
abnorrnal sensory studies. Motor abnormalities for 
a given patient tended to be homogeneous, with 
the lower limbs showing greater involvement than 
the uppcr limbs. Conversely, sensory studies fre- 
quently demonstrated abnormalities of individual 
nerves. Sural and median sensory conduction 
studies are shown in Table 3 .  During initial evalu- 
ation, a common finding was an abnormal median 
sensory response with normal sural nerve conduc:- 
tion studies.'9 'I'he median sensory nerve action 
potential (SNAP) usually was absent or markedly 
reduced in amplitude with prolonged distal la- 
tency. Patients wit.h an abnormal surd and normal 
median sensory conduction study, a firidirig char- 
acteristic of most mild, chronic polyneuropathies. 
were uncornmon. This finding of a normal, rela- 
tively spared sural response in the presence of an 
abnormal median sensory response, in association 
with the appropriate clinical syndrome, is chariic- 
teristic of AIDP. 
Several explanations exist for the discrepancy 
between motor and sensory studies as well as the 
discrepancy between the sural and median sensory 
conduction studies. Neurornuscular transmission 
failure following a distal axonal lesion would re- 
sult in reduc-ed CMAP amplit.udes prior to reduc:- 
tion in SNAP amplitutles. If the aniount of rriyeliri 
protected the axon or preserved conduction, the 
larger myelinated sensory fibers would be prefer- 
entially preserved relative to the smaller motor fi- 
bers. This also could explain prolonged sural 
nerve function compared to median sensory func- 
tion, because the sural recording is obtained from 
the more proxirnal nerve as compared with the 
terminal median sensory fibers. This distal predi- 
lection is consistent wirh reported centripetal de- 
rriyelinatiori in sonic patients" and also consistent 
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FIGURE 2. Serial ulnar compound muscle action potential amplitudes with proximal and distal stimulation, recording from the hypothe- 
nar muscles of a patient with acute inflammatory demyelinating polyneuropathy. Amplitudes (mV) are expressed as a function of time 
from disease onset. (Reprinted with permission from Albers JW: Electromyography in the prognosis of nerve injury. American Academy 
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FIGURE 3. Motor- (open bar) and sensory- (shaded bar) evoked 
response amplitudes expressed as a percentage of the normal 
mean as a function of time after disease onset in 70 patients 
with acute inflammatory demyelinating polyneuropathy. The re- 
sponses are significantly (P  < 0.05) different for weeks 1, 2, and 
3. No significant differences exist thereafter. (Reprinted from 
Ref. 2 by permission of John Wiley & Sons, Inc, Copyright Q 
1985.) 
with the observations of Sumner,H9 who found, us- 
ing a humorally induced demyelination in rat sci- 
atic nerve, that smaller diameter myelinated fibers 
were affected earlier and more completely than 
larger diameter fibers. Nerve roots were highly 
permeable to antiserum: and distal motor nerve 
twigs and cummon compression sites were identi- 
fied as potential areas of vulnerability because of 
an impaired blood-nerve barrier. 
Electromyography (EMG) has a secondary role 
in evaluating patients with AIDP. Decreased nio- 
tor unit action potential (MUAP) recruitment, 
without evidence of conliguration abnormalities or 
abnormal spontaneous activity, is the initial find- 
ing, reflecting the clinical distribution of weakness. 
Occasionally, myokymic discharges are observed 
during the first few weeks of illness.'s They may 
be found in facial or extremity muscles and may 
be present in the absence of clinical myokymia. Fi- 
brillation potentials and positive waves appear be- 
tween 2 and 5 weeks, sirnultarieously in proxiiiial 
and distal muscles (Fig. 4), consistent with either 
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Table 3. Comparison of median and sural sensory conduction studies in patients with acute Inflammatory demyehnating 
polyneuropathy results at the time of initial and follow-up evaluation 
All studies ( r i  = 86) Initial eval first 3 weeks (n = 39) Follow-UP (n = 39) 
Both normal 30 (35%) 11 (28%) 13 (33%) 
Median abnormal and sural rormal 36 (42%) 19 (49%) 13 (33%) 
Both abnormal 20 (23%) 9 (23%) 13 (33%) 
Median normal and sural abnormal 0 (0%) 0 (0%) 0 (0%) 
Source Mod/f/ed and reprmted from Ref 2 w/th the permission of John Wdey & Sons Inc Copyright 1985 
random axonal degeneration at any point along 
the axon or predominant distal involvement. 
Proximal fibrillation potentials are maximal be- 
tween 6 and 10 weeks, with distal fibrillation po- 
tentials persisting for many months. 'l'he amount 
of abriorrrial spontaneous activity ranges from 
none to extensive denerviition with profuse ( 4 t )  
positive waves and fibrillation potentials. The 
early reduction in fibrillation potentials in proxi- 
mal compai-ed with distal muscles likely reflects 
reinnervation from axonal sprouting or regenera- 
tion in proximal compared with distal muscles. 
This can be explained both by the greater proba- 
bility of' regeneration in a short axon and by the 
increased likelihood of' collateral reinnervation 
from a greater number of surviving axoris. 
Prognostic Indicators. Clinical and CSP findings 
are poor predictors of outmme in patients with 
A prolonged interval to onset of- recovery 
indicates a poor prognosis, LIS does rapid evolu- 
tion of weakness and ventilator dependency."5 
t i 0  , 
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FIGURE 4. Abnormal spontaneous activity in proximal (open 
bar) and distal (striped bar) muscles as a function of time after 
disease onset in 70 patients with acute inflammatory demyeli- 
nating polyneuropathy. Fibrillation potential scores range from 0 
to 4+, with 0 = none and 4+ = profuse fibrillation potentials in 
all areas of muscle. (Reprinted from Ref. 2 by permission of 
John Wiley & Sons, Inc., Copyright B 1985.) 
Nevertheless, some ventilaltor-dcpendent patients 
recover promptly arid comlpletely, whereas seem- 
ingly identical patients havq: a prolonged recovery. 
The most powerful predicwr of poor outcome is 
reduced ChilAP amplitude to less than 10% of the 
lower limit of nornial.6G Neurologic recovery is 
positively and significant11 correlat.ed with pre- 
served mean CMAP anipliitude, when the studies 
are performed between weeks 3 and 5. .I'hese 
findings support the hypothesis that evidence sug- 
gestive of predominant demyelination is corre- 
lated with relatively rapid recovery. whereas find- 
ings suggestive of severe ;ixonal destruction are 
correlated with slow rec~very."~'" The amount of- 
fibrillation is a relatively poor predictor of prog- 
nosis when used alone. 
Treatment. The supportive treatment of patients 
with AIDP involves maintenance of respiralory 
function and prevention of' circulatory failure arid 
throniboembolism.' The advent of respiratory 
intensive care units has been important in preserv- 
ing life, although a mortality rate of approxi- 
mately 5%' persists even with aggressive pulmon- 
ary treatment. Most dcatbs follow medical compli- 
cations of respiratory parxlysis, including pneu- 
rnonia.42 Approximately half. of patient deaths are 
sudden, presurndb\y related lo cardiac dysrhyth- 
mias or hypotension. All p;i.tients require observa- 
tion for respiratory deterio-ration. 'L'he decision of 
whether or  not to intubate a patient depends 
upon both the extent and rate of respiratory dete- 
rioration. General thresholds are difficult to de- 
fine, but intubation and rebpirator support gener- 
ally are needed if the forced vital capacity falls 
below 13 mlikg. Elective inrubation should be per- 
formed if there is a rapid decline of vital capa(:ity, 
early signs of h ypoxia, aspiration with poor tra- 
cheopulmonary toilet, pullnonary infection with 
shunting, or signs of' respiratory distress or fa- 
tigue. Arterial Mood pses  represent a poor mea- 
sure of respiratory function. detcriorating 1at.e in 
the clinical course. ,4 low 1 1 0 2  and low or normal 
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PCO, indicates shunting from early atelectasis and 
often precedes respiratory hi l~ire .  Hypercapnia is 
a late finding of respiratory failure and dangerous 
criterion for elective intubation. Prolonged intuba- 
tion without tracheostoniy is now possible with 
soft endotrachial tubes, although met.iculous tra- 
cheopulmonary toilet is hcilitated by trache- 
ostomy, and the use of' a talking tracheostoniy may 
facilitate psychological care. 
Autonomic instability requires monitoring in 
an intensive care setting. Hypotension is best man- 
aged by increasing fluids, and sympathominietics 
usually are avoided. Hypertension is best not 
treated unless severe. When necessary, rnedica- 
tions with a short half-life such as nitroprusside or 
propanalol are preferred. The most common car- 
diac dysrhythmias are a second- or third-degree 
AV block. Temporary pacemaker insertion is an 
effective treatment. 
Additional medical management includes 
proper bladder care, prompt identification and 
treatment of superimposed infection, restriction 
of fluids in patients who are hyponatremic, and 
antiembolism protection, including low-dose hepa- 
rin (5000 units subcutaneous twice daily) and anti- 
embolus stockings in quadriparetic patients. Ap- 
propriate laboratory studies should be performcd, 
nionitoring for occult blood loss, anemia and 
thrombocytopenia, infection, and electrolyte im- 
balance. 
Corticosteroids are of unproven efficacy in 
AIDP, and their use is corirroversial. The most re- 
cent controlled studyg9 reported that prednisone 
may have slowed the recovery rate and increased 
the chance of relapse. Anecdotal reports24 exist of 
single patients who responded dramaLically to sle- 
roids. 
The potential importance of humoral factors 
in the pathogenesis of AIDP suggested that thera- 
peutic plasma exchange (.l'PE) might modify the 
disease course." The niulticeri~er randomized 
trial of TPE in the treatment of ,41DP9" dcmon- 
strate'd significant benefit of TPE when compared 
with conventional medical treatment, excluding 
steroids. Hy all criteria, 'L'PE had a beneficial ef- 
fect. The median time on a respirator was re- 
duced by 1 1  days and the time to unassisted am- 
bulation shortened by an average of 73 days lor 
respirator-dependent patients who received TPE. 
Similar- rcsults have tieen reported in two ad- 
ditional controlled, randornized trials. "." Two 
smaller controlled trials were inconclusivc, al- 
though the trends favored the TPE group."'."3 
TPE is not effective for all patients. Patient age 
and the CMAP amplitudes are important predic- 
tors of early r e s ~ ~ ~ ~ i ~ s i " e , i ~ s s . ~ 4  TPE appears partic- 
ularly effect.ive for pat.ien ts who  begin treatment 
within 7 days of disease onset, although early, ag- 
gressive TPE may be associated with initial im- 
provetrierit followed by relapse, perhaps related to 
termination of treatment too early in the course of 
the disease." 
CHRONIC INFLAMMATORY DEMYELINATING 
POLYNEUROPATHY 
Clinical Features. CIDP is a chronic progressive 
or relapsing disorder' of peripheral nerves that 
c:linic:ally resembles AIDP. Reliable incidence esti- 
niat.es are unavailable, although it is probably less 
than that of AIDP. Because of the prolonged 
course, however, I he prevalence probably exceeds 
t.hat of AIDP. CIDP occurs in both sexes and all 
ages wilt1 little evidence of peaks other than a pre- 
dominance in the fifth and sixth  decade^.^' 
Diagnostic criteria differ o n l y  slightly for those 
used for AIDP. At present, the only reliable 
method for differentiating the two disorders is by 
an arbitrary clinical judgment regarding the tem- 
poral evolution of neurologic symptoms. Patients 
with CIDP usually have an interval between onset 
and peak impairment exceeding 4 weeks, and the 
average duration from onset to peak deficit aver- 
ages approxiniately 3 months, with a range of 3 
weeks to 16 months." 
CIDP is characterized by sensory loss and 
weakness, areflexia, elevated CSF protein, and 
electrodiagriostic evidence of multifocal demyeli- 
nation with or without superimposcd axorial 
degeneration.~5~'fi~''1 'I'he etiology is unknown, but 
the results of nerve biopsy and reports of re- 
sponse to s t e r o i c ~ s , ' ~ ' ~ ~  a a t l i i op r ine , '~ .~~  or 
suggest an immunologic etiology." TPE":' ,84,85,92 
An identifiable antecedent event is rare compared 
with AIDP, although CIDP has been associated 
witti iiniiiune complexes of tiepatitis B virus.41 
Symmetric sensory aridior motor symptoms are 
the initial manifestation, and weakness usually be- 
gins in the legs. Karely, asymmetric findings are 
present, consistent with rnultifocal demyeliriatirig 
mononeuropathies.~' Cranial nerve involvenient is 
common, especially orbicularis oculi weakness, but 
less prominent than iii AIDP. Maximal weakness 
usually is distal, and 15 of the 23 patients de- 
scribed by Prineas arid McLeod" were nonambu- 
latoi-y during their most severe episode. Occa- 
sional patients require respiratory support, either 
during an exacerbation or during the terminal 
phase. Muscle wast.ing may bc severe but often is 
~~ 
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rnild compared with the degrec and severity of 
muscle weakness. Sensory symptoms and signs usu- 
ally are mild but may be associated with a sensory 
ataxia. All modalities of sensation may be affect- 
ed." although large fiber loss predominates. Mus- 
cle stretch reflexes are usually absent at some time 
during the illness; rare patients fulfill all other di- 
agnostic criteria but have hypoactive, preserved 
reflexes. Autonomic involvement is uncommon. 
The clinical course in CIDP is variable. The 
term chronic relapsing polyneuropathy (CRP) has 
been used to describe patients with clear relapses 
and remissions. Dyck and associates26 estimated 
that approximately 50% of- patients had a progres- 
sive course (slow or stepwise), one-third had a re- 
lapsing course, arid the remaining patients experi- 
enced a monophasic illness with the peak deficit 
remaining or developing after 6 months. W-ith 
current treatments, many patients who may have 
had progressive disease seemingly respond to 
treatment but relapse when therapies are tapered 
or discontinued. The distinction between therapy- 
associated relapse in CIDP and idiopathic relapse 
in CRP is unclear. 
In CRP, the average interval between relapses 
is about 10 months, although relapses have been 
reported 3 1 years after initial attacks.77 Patients 
with CRP may remit after many years, without 
further exacerbations. In early reports of outcome 
for 53 patients with CIDP who were followed for 
an average of 7 years, 9 died (6 from the disease), 
6 were confined to wheelchair or bed, 36 had a 
mild to moderately severe impairment, and only 2 
had complete resolution.26 Recent experience sug- 
gests that more patients experience remission, 
with fewer patients demonstrating progressive de- 
terioration. This may reflect earlier detection and 
treatment or recognition of milder cases. 
Electtophysiologic Features. The electrodiagnos- 
tic findings in CIDP resemble those described late 
in the course of AIDP and are consistent with 
multifocal demyelination with variable amounts of 
superimposed axonal degeneration. The chronic 
progressive, stepwise progressive, and relapsing 
forms cannot be differentiated electrophysiologi- 
cally. Electrodiagnostic criteria suggestive of de- 
myelination in CIDP ('Table 4) differ slightly from 
those described for AIDP. These differences re- 
flect the possible development of axonal stenosis 
or regeneration, changes that may result in sub- 
stantial conduction slowing without segmental de- 
myelination. Nevertheless, electrodiagnostic evi- 
dence of demyelination is present in virtually all 
patients with CIDP, and many consider this part 
of the diagnostic criteria. Motor conduction ve- 
locities may be markedly reduced, F response la- 
tencies very prolonged (or absent), and temporal 
dispersion more prominent than observed in 
AIDP, although individual variations are large. 
The combination of absent or abnormal SNAPS 
with normal sural responses occurs but is uncom- 
mon in CIDP compared with AIDP. EMG abnor- 
malities are present in most patients with CIDP. 
Like AIDP, needle examination is useful for de- 
fining the chronicity and extent of axonal degen- 
eration. 
Treatment. The supportive care of patients with 
CIDP is identical to that described for AIDP. Un- 
like AIDP, corticosteroids are of demonstrated 
benefit in controlled trials of both the CRP and 
CIDp.8,26,27,77,91 Many prednisone treatment pro- 
tocols exist, including high-dose daily or alternate- 
day schedules, with slow taper depending upon 
clinical response. Azathioprine also has been re- 
ported to be effective in several case reports and 
small clinical trials of CIDP patients,94 including 
patients previously steroid unresponsive or intoler- 
ant. 
Isolated case re orts described TPE as benefi- 
in (;IDp."',5Y,6r84 A consecutive patient trial 
of TPE demonstrated substantial clinical improve- 
ment within 3 weeks in about 50% of progressive 
CIDP patients." The temporal association be- 
tween improvement and TYE in patients with 
72 
Table 4. Criteria suggestive of dernyelination in the electrodiagnostic evaluation of chronic inflammatory polyneuropathy 
Evaluation should satisfy at least three of the following in motor nerves (exceptions noted below) 
1 Conduction velocity less than 75% of the lower limit of normal (two or more nerves) a 
2 Distal latency exceeding 130% of upper limit of normal (two or more nerves) 
3 Evidence of unequivocal temporal dispersion or conduction block on proximal stimulation consisting of a proximal-to-distal 
amplitude ratio less than 0 7 (one or more nerves) 
4 F-response latency exceeding 130% of upper limit of normal (one or more nerves) a 
"Exciudmg /solafed ulnar or peroneai nerve abnormalmes at the elbow or knee, respectwely 
'Excludmg /so/ated m e d m  nerve abnormahty at the wnst 
'Excludmg the presence of anomalous innervation (e g medmn to ulnar nerve crossover) 
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longstanding, progressive deterioration seemed 
more than coincidental. A subsequent prospective 
double-blind trial in which patients with static or 
progressive CIDP were randomized to TPE or 
sham exchange groups demonstrated significant 
improvement in electrodiagnostic and clinical 
measurements after 3 weeks, favoring patients re- 
ceiving TPE? 
DYSPROTElNEMlC OR PARANEOPLASTIC 
NEUROPATHIES 
A subset of patients with acquired dcmyelinating 
polyneuropathy exists which differs from CIDP 
only by the presence of an underlying systemic ill- 
ness. Because the systemic illness may not be ap- 
parent when the polyneuropathy is diagnosed, 
these patients often are classified as having CIDP 
or even RIDP, although most clinicians restrict 
these terms lo exclude patients with systemic ill- 
ness. Included are atients with Waldenstrorn's 
* n a c r ~ ) ~ l o ~ ~ u I i n e ~ i i a , ' ~  gan rria heavy chain dis- 
ease:" cryoglob~linemia,~~ lymphoma,"' systemic 
 UPU US erythematosus,26 Castleman's disease, l4 and 
HIV I 
Acquired demyelinating polyneuro athy rarely 
can be due to an occult malignancy.'' The poly- 
neuropathy with malignancy can be motor domi- 
nant, distal and/or proximal in distribution, evolve 
rapidly or slowly, and develop a relapsing or re- 
mitting course. EMG and pathologic studies are 
the same as in idiopathic cases. The etiology is as- 
sumed to be an irnmunologic process triggered by 
the underlying malignancy. The association is 
rare, however, and there is no reason to routinely 
evaluate all patients for a malignancy. Far more 
common is the association of an acquired demyeli- 
nat.ing polyneuropathy and a plasma cell dyscrasia 
syndrome. Because of the high prevalence com- 
pared with other systemic disorders, these syn- 
dromes will be described further below. 
Demyelinating Polyneuropathy Encountered in the 
Plasma Cell Dyscrasia Syndromes. All idiopathic 
polyneuropathy patients, anti particularly those 
with presumed CIDP, should be evaluated for 
possible occult plasma cell dy~crasias.'~ '4 sug- 
gested approach is detailed in Table 5. Up to 10% 
of patients with idiopathic polyneuropathy harbor 





Regular neuropathy evalution + SPEP 
I 
.1 J .1 
5 
SPEP abnormal SPEP nornial SPEP normal 
(neuropathy severe) (neuropathy mild) 
Treat symptoms + follow 
(if neuropathy worsens) 
v 
Serum + urine IEP 
or IF, 24 hr urine protein 
4 
If M protein found 
i 
Rematology evaluation 
(bone marrow, rectal 
2 nerve biopsy, 
skeletal survey, etc.) 
I 





I f  no M protein found 
Consider sural nerve biopsy for amyloid 
and irnrnunofluorescence, consider 
metastatic skeletal survey 
--i If positive 
If negative I f  MGUS I 
Continue evaluation for idiopathic PN 
Follow and reassess every year, treatment 
as needed 
__ -
SPEP = serum protein electrophoresis. IEP = ,mmunoelectrophoresrs, IF - imrnunohxation, MGUS ~ monocbnal gammopathy 
Source Reprinted with permission from Kelly JJ Polyneuropathies associated with plasma cell dyscrasias, in Brown MJ fed) Seminars in neurobgy 
Neuropathy 7 30-39 1987 
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Table 6. Features of polyneuropathy M protein syndromes 
Type of Sensory Autonomic CSF protein 
polyneuropathy Topography Weakness loss loss Course elevation Pathology EMG 
MGUS (IgM) Distal, symmetric ++ +++ 0 Chronic ++ SD Slow CV 
MGUS Distal, rarely ++  ++ + Chronic ++ SD Slow or mildly slow 
proximal CV 
AL Distal, symmetric +/++ +++  ++ Chronic ~ + AD Mildly slow CV 
UgG, IgA) 
QSM Distal, symmetric + + + +r 0 Chronic + +i+ + + SD Slow CV 
WM Distal, symmetric ++ ++ 0 Chronic ++  SD Slow CV 
(AD) 
Note 0 = none. 2 = equivocal or occasional, + = minimal, ++ = moderate, +++ = marked, MGUS = monoclonal gammopathy, AL = amyloidosis, 
OSM = osteosclerotic myeloma WM = Waldenstrom’s macroglobulinemia. SO = segmental demyelination, AD = axonal degeneration. CV = conduction 
velocity 
Source Reprinled with permission from Kelly JJ Polyneuropathies associated with plasma cell dyscrasias, in Brown MJ (ed) Seminars in neurology 
Neuropathy 7 30-39, 1987 
an occult plasma cell dyscrasia which may directly 
relate to the etiopathogenesis of the neuropathy 
and respond to treatment. These patients are of 
investigational importance because the mono- 
clonal protein may cauSe the polyneuropathy. The 
features of the polyneuropathy in the different 
plasma cell dyscrasia syndromes are summarized 
in Table 6. 
Primary systemic amyloidosis of the amyloiti 
light-chain type forms an important subset of the 
plasma cell dyscrasia syndromes. The polyneurop- 
athy, however, is axonal and usually involves srnall 
fibers without evidence of conduction slowing, 
and therefore should not be confused with the de- 
rnyelinating dysimniune polynenropathies. Simi- 
larly, typical multiple myeloma is associated with a 
very high monoclonal protein le~e l ,  widespread 
lytic skeletal lesions, anemia, and hypercalcemia. 
It is rarely associated with polyneur~pathy .~~ 
When it is, polyneuropathy is heterogeneous in 
type with little relationship to the status of the niy- 
elotna. 
Monoclonal Gammapathy of Undetermined Signifi- 
cance. In evaluating patients with presumed 
CIDP, a monoclonal gammopathy occasionally is 
identified. This hematologic disorder, referred to 
as monoclonal gammopathy of undetermined sig- 
nificance (MCUS), was formerly called “benign 
monoclonal gammopathy” but was renamed be- 
cause up to 20% of these patients develop more 
serious hematologic disease or secondary changes 
elsewhere, including n e ~ r o p a t h y . ~ ~  By definition, 
these patients have a low monoclonal protein con- 
centration (<3 g/dl), no malignant plasma cell in- 
filtration of the bone marrow, and no bony lesions 
(Table 7). This group accounts for about one-half 
of plasma cell dyscrasia, polyneuropathy patients 
(Table 8). 
Patients with MGUS-associated neuropathy in- 
clude IgM and non-IgM types. The IgM group is 
of int.erest because one-half of these patients have 
a characteristic polyneuropathy , and the n1ono- 
clonal immunoglobulin possesses antinerve activ- 
ity,  most commonly directed at an antigen on the 
Table 7. Hematologic diagnostic criteria of M protein syndromes 
Syndrome Anemia M protein serum M protein urine Bone marrow Skeletal survey Tissue biopsy 
MGUS No +* ? 2 Normal - 
AL +/-t + ++ + + Normal ++ (amyloid) 
MM -t + + +++*’ ++ +++ Abnormal (Iytic) + + + (myeloma) 
OSM No + * h  No ++i+++ Abnormal (sclerotic) + ++ (sclerotic myeloma) 
WM +++ +++**  ? + + I + + +  f ~ 
GAMMA-HCD + + + + + ++ N ~ 
Note. -t = equivocal or occasional, + = rare, t + = common, + + + = almost always or severely abnormal, MM = multiple myeloma, Gamma-HCD = 
gamma heavy-chain disease, other abbreviations same as Table 6. 
* Less than 3 g per deciliter 
If More than 3 y per deciliter 
A = Almost always lambda light chain. 
Source. Reprintcd with permission from Kelly JJ: Polyneuropathies associafed with plasma cell dyscrasias, in Brown MJ (ed) Seminars in neurology. 
Neuropathy 7.30-39, 1987. 
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Table 8. Final hematologic diagnosis in 28 patients with spond to immunosuppression. The mechanism of 
polyneuropathy and M proteins nerve fiber damage is unknown. 
Patients with the IgG or IgA polyneuropathies 
are a heterogeneous group, and a relationship, if Monoclonal gammopathy of undetermined significance Arnyloidosis light-chain type 7 
Myeloma (including osteosclerotic cases) any, between the gammopathy and polyneuropa- 
Waldenstrom s rnacroglobulinemia 1 thy is not clear. Nevertheless, such patients may 
Gamma heavy-chain disease 1 have an unequivocal demyelinating polyneuropa- 
Total 28 thy indistinguishable from patients with GIDP- or 
IgM-associated dysimmune neuro athy . Response Source Repnnted with permmion from Ref 46 
to immunosuppression is variable. 
16 
!7 
myelin sheath.36*" The vast majority of patients 
with antinerve-reactive IgM polyneuropathy have 
a slowly progressive, sensory polyneuropathy 
which superficially resembles the sensory neuron- 
opathy syndrome seen with cancer. These neurop- 
athies, however, tend to be much more chronic 
and indolent, and weakness and atrophy may de- 
velop when the neuropathy is advanced. Pansen- 
sory impairment with sensory ataxia occurs. Other 
cases are very mild and nonprogressive over sev- 
eral years. Electrodiagnostic findings differentiate 
these patients from those with pure sensory neu- 
ronopathy. Motor conduction is markedly slowed 
in the range associated with segmental demyelin- 
a t i ~ n , ~ '  and CMAP amplitudes are reduced. Nee- 
dle EMG confirms loss of motor axons. The CSF 
protein is usually markedly elevated unless the 
polyneuropathy is very mild. 
Nerve biopsy demonstrates combined axonal 
degeneration and demyelination. Direct immuno- 
fluorescent staining for  immunoglobulin^^^ shows 
deposition of monoclonal IgM (Fig. 5) on the my- 
elin sheath. The monoclonal protein is almost 
always of the kappa light-chain type. Studies 
have demonstrated in vitro reactivity of this im- 
munoglobulin with myelin-associated glycoprotein 
(MAG) and other carbohydrate epitopes of glyco- 
proteins or glycolipids on the myelin shcath.40 
Treatment with immunosuppressives and T'PE 
decreases the itnniunoglobulin level and patients 
may improve (Ref. 87 and Kelly et al., unpub- 
lished). Injection of serum from these patients 
into animal nerves causes focal d e m y e l i n a t i ~ n . ~ ~  
Karely, other IgM polyneuropathies are associated 
with axonal degeneration, and IgM is deposited 
on axons and perineurial tissue. Studies have 
shown in vitro reactivity with axonal pellets and 
axonal antigens such as chondroitin sulfate.86 
Patients with nonreactive IgM neuropathies 
form a more heterogeneous group. Some closely 
resemble MAG-reactive polyneuropathies, and 
some resemble axonal neuropathy. They may re- 
Osteosclerotic Myeloma. Osteosclerotic myeloma 
differs from typical multiple myeloma.45 Less than 
3% of patients with osteosclerotic myeloma ac- 
count for about two-thirds of cases of polyneurop- 
athy in large myeloma series; about one-half of all 
osteosclerotic myeloma patients have a polyneu- 
ropathy. Osteosclerotic myeloma is more indolent 
than multiple myeloma, occurs at a younger age, 
and is associated with longer survival. The poly- 
neuropathy tends to be slowly progressive, distal, 
symmetric, and mainly motor, without autonomic 
dysfunction. CSF protein is very high, and there is 
frequently papilledema. 
Electrodiagnostic findings"343s45 include 
marked slowing of motor nerve conduction veloc- 
ities, partial conduction block, and prolonged or 
absent F-response latencies. SNAPS are decreased 
or absent. EMG needle examination shows acute 
and chronic neurogenic changes. Most patients 
have nionoclonal protein of the lgG or IgA and 
lambda light-chain type, but occasionally, kappa 
light-chains are present. There are no reports of 
direct immunofhorescent staining of nerves from 
these patients, and the monoclonal protein is not 
MAG-rea~tive.~' Microinjection of the serum into 
animal nerves does not cause focal demyelination 
or conduction The key to diagnosis is rec- 
ognition of the monoclonal protein and bony le- 
sions. 
The polyneuropathy resembles monophasic 
CIDP, and consideration of this diagnosis man- 
dates protein studies and a metastatic skeletal sur- 
vey. Bony lesions occur in the proximal skeleton 
and may be sclerotic or mixed sclerotic and lytic 
(Fig. 6). Biopsy of any suspicious lesion is manda- 
tory. Treatment depends on the nature of the 
plasmacytoma. If solitary, surgical extirpation or 
radiation therapy is indicated, and patients im- 
prove following effective treatment. Many, or pos- 
sibly all, eventually relapse. If lesions are multiple, 
chemotherapy occasionally provides benefit.21 
Some patients' develop widespread findings 
with polyneuropathy, organomegaly, endocrinop- 
Inflammatory Dernyelinating Polyneuropathy MUSCLE & NERVE June 1989 445 
FIGURE 5. lmmunofluorescent staining shows intensely stained deposits of IgM especially along the outer lamellae of the myelin 
sheaths of myelinated axons. Less intense staining is seen around the  axon. (Reprinted from Ref. 37 with permission.) 
FIGURE 6. Osteosclerotic lesions in patients with polyneuropathy (A) Mixed lytic and sclerotic lesion of the left ilium in a 56-year-old 
woman (B) Multiple sclerotic lesions involving vertebral bodies, sacrum, ischium, and pelvis in a 42-year-old man (C) “Ivory” L-3 ver- 
tebra in a 47-year-old woman. (Reprinted from Ref. 45 with permission ) 
athy, M protein, and skin changes (POEMS syn- 
drome). This multisystem disorder also has been 
called “Crow - Fukase syndrome” and “Takatsuki’s 
sy~idrome”.’~ None of these terms is satisfactory 
because they are too restrictive. Most of these pa- 
tients have monoclonal proteins of the IgG or lgA 
type with lambda light-chains. One-half to two- 
thirds have osteosclerotic lesions. ‘I’he common 
denominator may be the lambda light-chain or 
some other secretory product of the plasma cell le- 
sion. Thus, osteosclerotic myeloma may be one 
end of a spectrum, with POEMS at the other. 
‘=I 
CONCLUSION 
Patients with acquired demyelinating polyneurop- 
athies comprise a substantial portion of those 
patients with undiagnosed polyneuropathies pre- 
senting for evaluation. -1’heir importance is dis- 
proportionate to their numbers, since many are 
treatable, some are associated with unrecognised 
systemic disorders, and most provide clues to the 
etiopathogenesis of other obscure neuropathies. 
Although their relationship is unclear, the acute, 
chronic, and dysimmune infiammator y dernyeli- 
nating polyneuropathies have characteristic pre- 
sentations, some of which are easily recognized. 
Not surprisingly, the electromyographer plays a 
central role in the evaluation of these patients and 
is in a position to recognize the patterns of in- 
volvement and suggest possible diagnostic alterna- 
tives. Thus, the ability to identify an acquired 
demyelinating polyneuropathy, coupled with a 
thorough knowledge of these syndromes, is ini- 




(CMAP) shown below each nerve in the schematic screen. Indi- 
vidual axons are of slightly different sizes and therefore conduct 
at different rates. Muscle fibers are denoted bv solid bars to the 
Motor Nerve Model: Prediction of Electrodiagnostic 
Findings in M’ltifocal Demyelinationm A silnple 
model of the peripheral motor nerve can pre- right of each axon Arrows represent stimulation sites Upper re- 
dict electrodiagnostic findinns in acute inflamma- cording resultant CMAP following distal nerve stimulation ” ” 
tory demyelinating polyneuropathy (AIDP). ’lhis 
model, together with empiric electrodiagnostic 
observations, can be used to anticipate the elec- 
Lower recording: resultant CMAP following proximal nerve stim- 
ulation. (Reprinted from Ref. 1 with the permission of Butter- 
worths, Copyright 6 1987). 
trodiagnostic findings for acute, multifocal demy- 
elination. ‘I’he model is represented in Figs. 7-9, 
consisting of eight axons of variable diameter, 
ranging from the largest (top) to smallest (bot- 
tom). Individual muscle fiber action potentials 
(MFAPs) are shown to the right of each axon fol- 
lowing stimulation of all axons (arrow). Conduc- 
tion is fastest in the largesl and slowest in the 
smallest axon; the difference in conduction bc- 
tween the largest and smallest fibers constitutes 
the range of conduction velocities. Individual 
MFAPs dre summed to obtain a compound muscle 
action potential (CMAP), shown below the mod- 
eled Ilene. In the figures, the simulated CMAP is 
demonstrated for distal nerve stiniulation (upper 
half of each figure) and proximal nerve stimula- 
tion (lower half of each figure). Latencies could be 
calculated and a conduction velocity for the fastest 
axon determined using the distance between stim- 
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FIGURE 8. Computerized model of axonal degeneration in pe- 
ripheral motor nerve described in Fig. 7, following random loss 
of 75% of axons. Resultant CMAP after distal (upper screen) 
and proximal (lower screen) stimulation. Arrows represent stim- 
ulation sites. (Reprinted from Ref. 1 with the permission of But- 
terworths, Copyright 6 1987). 
ulation sites. In this model of normal nerve (Fig. 
7), the CMAP amplitude can be iiieasured follow- 
ing proximal and distal stimulation. The reduced 
CMAP amplitude following proximal stimulation 
reflects the expected temporal dispersion of indi- 
vidual MFAPs and would be increased if either 
the distance between stimulation sites or the range 
of conduction velocities were increased. 
Following extensive axorial dcgerieratiori (Fig. 
8), CMAP amplitude diminishes for both proximal 
arid distal st.irriulation with little change in distal 
latency or conduction velocity. If' the largest axon 
had remained intact, conduction velocity anti tlis- 
1-1 
FIGURE 9. Computerized model of multifocal demyelination in 
peripheral motor nerve described in Fig. 7. Resultant CMAP af- 
ter distal (upper screen) and proximal (lower screen) stimula- 
tion. Arrows represent stimulation sites. The diminished CMAP 
amplitude with proximal stimulation results from temporal dis- 
persion of individual muscle fiber action potentials and conduc- 
tion block in some axons. (Reprinted from Ref. 1 with the per- 
mission of Butterworths, Copyright 0 1987.) 
tal latency would have been unchanged. The 
greatest abnormality relative to axonal degenera- 
tion would result if only the smallest fiber re- 
mained. Both conduction velocity and distal la- 
tency would be abnormal, but the magnitude of 
abnormality would be small compared with the re- 
duced CMAP amplitude. 
For comparison, random, multifocal demyeli- 
nation is denionstrated in Fig. 9. I n  the model, 
propagation is slowed across a single dernyeli- 
riated node, arid conduction is blocked if  two ad- 
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jacent nodes a1-e dcrnyclinated. With distal stimu- 
lation, CMAP amplitude is slightly reduc:ctl arid 
duration slightly increased because of increased 
dispersion. Dist.al latency is slightly prolonged be- 
c;iuse the largest two fibers are cicm yelinated dis- 
tally bui. the third largest fiber is intact. Proximal 
stimulation results in pronounced temporal dis- 
persion of the (;MAP, explained by the variable 
amounts of demyclination i r i  some axons corn- 
pared with the others, producing an incrcasc in 
the range of conduction velocity. ‘This results in 
the initial component of the CMAP (rcpresenting 
the fastest conduction time) being greatly sepa- 
rated from the trailing portion of the CMAP 
(representing the slowest conducting axon). l h e  
CMAP amplitude with proximal stimulation is 
reduced to a great-er extent than can be ex- 
plained by temporal dispersion alone, because of 
conduction block in two of the axons. The likcli- 
hood of continuous propagation along the nerve 
dccreares with increasing iiber length because of 
thc incrcasctl probability of having dernycliriatiori 
in two adjacent n o d c x  F response latencies would 
be increased or unobcainablc, depending upon 
h e  extent of conduction block. The findings 
of abnornral temporal dispersion and partial 
conduction block are very useful in establishing 
a diagnosis of acute inllanimalory polyneuropa- 
thy.  A representative recording from a patient 
early in the course of inflamrnatory polyneuropa- 
thy is shown in Fig. 1 for comparison to the 
model. 
The prescrice of abnormal temporal disper- 
sion is useful in distinguishing acquired demyeli- 
nating neuropat hies from hereditary deniyelinat- 
ing ncuropathie ’ I n  the latter, demyelination is 
uniform and involves all fibers. The range of 
conduction velocity is not dramatically increased, 
because all fibers demonstrate conduction slowing 
to a similar exlcrit. ‘I’herefore, conduction veloc- 
ity may be niarkcdly slowed, but abnormal tern- 
poral dispersion does no1 result. 
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